TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12828588

Group type: EXPERIMENTAL
Intervention: Chiron Hib/AlPO4 vaccine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: VaxemHib (aluminum hydroxide adjuvant) vaccine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: HibTiter (no adjuvant)
Number of subjects: 520
Study: 10898671

Group type: EXPERIMENTAL
Intervention: Piperacillin plus tazobactam (monotherapy)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Piperacillin plus tazobactam plus amikacin (combined therapy)
Number of subjects: 241
Study: 8925982

Group type: EXPERIMENTAL
Intervention: Transurethral closed bladder drainage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transurethral open bladder drainage
Number of subjects: 50
Study: 1505153

Group type: EXPERIMENTAL
Intervention: 6 mg/kg of liquid ibuprofen
Number of subjects: 39

Group type: COMPARATOR
Intervention: 10 to 15 mg/kg of liquid acetaminophen (mean dose 11.6 +/- 0.7)
Number of subjects: 39
Study: 6512582

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine/cyclophosphamide/dactinomycin and vincristine/doxorubicin/dacarbazine at six-week intervals for one year)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy, evaluated at six-week intervals)
Number of subjects: 61
Study: 30864450

Group type: EXPERIMENTAL
Intervention: BMI categorization based on nutritional status
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) and waist-height index (WHI)
Number of subjects: 537
Study: 29950170

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing newborn screening (NGS-NBS)
Number of subjects: 400
Study: 26076002

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for chronic musculoskeletal pain
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Changes in pain
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Changes in depression/anxiety
Number of subjects: 250
Study: 24844862

Group type: EXPERIMENTAL
Intervention: THRIVE score
Number of subjects: 0
Study: 22997893

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (0.01 mg/kg before anesthesia and 0.015 mg/kg in CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (placebo)
Number of subjects: 40
Study: 20175107

Group type: EXPERIMENTAL
Intervention: Post-bereavement negative events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for current externalizing symptoms and recent negative events
Number of subjects: 0
Study: 18602375

Group type: EXPERIMENTAL
Intervention: High monetary incentives for correct performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased task demands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negatively perceived prospects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased preparatory cognitive control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral OFC activity
Number of subjects: 0
Study: 15526142

Group type: EXPERIMENTAL
Intervention: NT 201 (4 units)
Number of subjects: 14

Group type: COMPARATOR
Intervention: BOTOX (4 units)
Number of subjects: 14
Study: 14663031

Group type: EXPERIMENTAL
Intervention: Idebenone 120 mg tid
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Idebenone 240 mg tid
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Idebenone 360 mg tid
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Idebenone (combined treatment groups)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo (combined treatment groups)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Idebenone (all groups)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo (all groups)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Secondary outcome measures
Number of subjects: 536
Study: 10469959

Group type: EXPERIMENTAL
Intervention: Antegrade crystalloid cardioplegia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Aprotinin administration
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Electrical defibrillation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Presence of a main stem lesion
Number of subjects: 62
Study: 8339631

Group type: EXPERIMENTAL
Intervention: NIC SR 30 mg twice daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: NIC SR 45 mg twice daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: NIC SR 60 mg twice daily
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Combined NIC SR groups
Number of subjects: 264
Study: 3525264

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.1%
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.25%
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5%
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control lesions
Number of subjects: 152
Study: 30289026

Group type: EXPERIMENTAL
Intervention: Blackadder blackcurrant juice (500 mg polyphenols)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study: 29740854

Group type: EXPERIMENTAL
Intervention: Fatherhood intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Financial literacy comparison condition
Number of subjects: 0
Study: 27323443

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (needling dorsal segment of the Governor Vessel, 7 spots below the spinous processes from T3 to T9)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Number of subjects: 60
Study: 25387891

Group type: EXPERIMENTAL
Intervention: Near focus optical diagnosis
Number of subjects: 558

Group type: COMPARATOR
Intervention: Standard view optical diagnosis
Number of subjects: 558
Study: 24142782

Group type: EXPERIMENTAL
Intervention: New formulation of fluticasone 125 μg BID
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: New formulation of fluticasone 250 μg BID
Number of subjects: 457

Group type: COMPARATOR
Intervention: Fluticasone DPI 500 μg BID
Number of subjects: 457
Study: 21875351

Group type: EXPERIMENTAL
Intervention: Oral GSH supplementation (500 mg twice daily for 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19194319

Group type: EXPERIMENTAL
Intervention: Baseline replication capacity (RCBL)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Week 48 CD4 increase (DeltaCD448)
Number of subjects: 321
Study: 16957530

Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15058892

Group type: EXPERIMENTAL
Intervention: Aerobic intensity program (n = 34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control intensity program (n = 32)
Number of subjects: 66
Study: 12791001

Group type: EXPERIMENTAL
Intervention: Oral loperamide (12 mg daily, 4 mg t.d.s.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Suppository loperamide (12 mg daily, 6 mg b.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral loperamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Suppository loperamide
Number of subjects: 10
Study: 11273109

Group type: EXPERIMENTAL
Intervention: Enalapril/captopril
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional treatment (digitalis and diuretics)
Number of subjects: 25
Study: 8294092

Group type: EXPERIMENTAL
Intervention: Diuretics alone
Number of subjects: 21
Study: 2646188

Group type: EXPERIMENTAL
Intervention: urapidil 60 mg (morning and evening)
Number of subjects: 168

Group type: COMPARATOR
Intervention: nifedipine retard 20 mg (morning and evening)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: urapidil
Number of subjects: 168

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 168
Study: 31621258

Group type: EXPERIMENTAL
Intervention: Pre-acupuncture at Neiguan (PC 6) and Zusanli (ST 36), once a day for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 50
Study: 28356097

Group type: EXPERIMENTAL
Intervention: Static goals
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adaptive goals
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Immediate rewards
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed rewards
Number of subjects: 96
Study: 26170035

Group type: EXPERIMENTAL
Intervention: Intensive case management (ICMM)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Linkage model (LM)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 521
Study: 24074357

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 80
Study: 21235465

Group type: EXPERIMENTAL
Intervention: Test formulation of diclofenac sodium (75 mg/mL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Reference formulation of diclofenac sodium (75 mg/3 mL)
Number of subjects: 14
Study: 18480187

Group type: EXPERIMENTAL
Intervention: Psychological stress task (8 minutes)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Psychological stress task (similar to experiment 1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mental stress task
Number of subjects: 118
Study: 16930104

Group type: EXPERIMENTAL
Intervention: Normal saline (NS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Heparinised saline (HS)
Number of subjects: 65
Study: 15966561

Group type: EXPERIMENTAL
Intervention: Early gonadotropin-releasing hormone (GnRH) agonist cessation protocol with leuprorelin 0.5 mg for 10-14 days followed by high doses of gonadotropins.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose flare protocol utilizing oral contraceptive priming followed by diluted doses of leuprorelin 50 microg twice daily and high doses of gonadotropins.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline ultrasound measurements predicting low response to IVF therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian stromal blood flow measurement.
Number of subjects: 0
Study: 10889565

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA(R))
Number of subjects: 178
Study: 9155717

Group type: EXPERIMENTAL
Intervention: CFTR cDNA-liposome complexes delivered by topical application
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo control (liposome alone)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CF subjects (combined treatment and control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-CF subjects (surgically resected tissues)
Number of subjects: 12
Study: 8174966

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Patients without autonomic neuropathy)
Number of subjects: 30
Study: 3492358

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g every 12 hours for a mean duration of 11 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Co-trimoxazole 1 double-strength tablet every 12 hours for a mean duration of 13 days
Number of subjects: 42
Study: 29407501

Group type: EXPERIMENTAL
Intervention: Bimaxillary miniplates-based skeletal anchorage
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 28
Study: 27644672

Group type: EXPERIMENTAL
Intervention: Ginger (500 mg capsules, 2 times a day for 10 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Chamomile (500 mg capsules, 2 times a day for 10 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (routine antiemetic regimen consisting of DMA capsules)
Number of subjects: 65
Study: 25399007

Group type: EXPERIMENTAL
Intervention: Aspirin (200 mg before surgery, then 100 mg daily for up to 30 days after surgery)
Number of subjects: 6905

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg before surgery, then transdermal patch providing 0.2 mg/d for 72 hours after surgery)
Number of subjects: 6905

Group type: EXPERIMENTAL
Intervention: Aspirin (presence of major bleeding)
Number of subjects: 6905

Group type: EXPERIMENTAL
Intervention: Clonidine (presence of clinically important hypotension)
Number of subjects: 6905
Study: 22858211

Group type: EXPERIMENTAL
Intervention: Early switch to duloxetine 60-120 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional switch to escitalopram
Number of subjects: 0
Study: 20394790

Group type: EXPERIMENTAL
Intervention: Electrically heated cigarette smoking system (EHCSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cigarette smoking (CC)
Number of subjects: 0
Study: 18042650

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15773825

Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs) in migraineurs
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs) in migraineurs without aura
Number of subjects: 181

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Pattern-reversal Visual Evoked Potentials (VEPs)
Number of subjects: 181
Study: 11799376

Group type: EXPERIMENTAL
Intervention: Probiotics administered to mothers during pregnancy and lactation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo administered to mothers during pregnancy and lactation
Number of subjects: 62
Study: 10522061

Group type: EXPERIMENTAL
Intervention: Lentinan, tegafur, and cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (tegafur and cisplatin)
Number of subjects: 0
Study: 7553676

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 232
Study: 1950714

Group type: EXPERIMENTAL
Intervention: Study I
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Study II
Number of subjects: 241
Study: 6248395

Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Orciprenaline (10 mg)
Number of subjects: 44
Study: 31036105

Group type: EXPERIMENTAL
Intervention: Chloroquine (250 mg twice daily per oral, 10 mg/kg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Doxycycline (200 mg daily per oral, 3.3 mg/kg/day)
Number of subjects: 50
Study: 28005578

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 27113284

Group type: COMPARATOR
Intervention: Podiatric management and placebo phototherapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Podiatric management with phototherapy on the ulcer(s)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Podiatric management with phototherapy applied to the regional lymphatic nodes and ulcer(s)
Number of subjects: 3
Study: 23368510

Group type: EXPERIMENTAL
Intervention: Lixisenatide QD (10 µg weeks 1-2, then 20 µg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 148

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 148
Study: 20309523

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily, self-administered injections at bedtime for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (Control group)
Number of subjects: 20
Study: 19441870

Group type: EXPERIMENTAL
Intervention: AliskirenHydrochlorothiazide (Aliskiren + HCTZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 0
Study: 16505130

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 15 sessions
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sertraline (SSRI) with a maximum dosage of 150 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study: 14753333

Group type: EXPERIMENTAL
Intervention: Conventional incremental technique (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Novel curing devices (Group B and C)
Number of subjects: 33
Study: 11801195

Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wrist splinting during the night for at least 6 weeks
Number of subjects: 0
Study: 9344302

Group type: EXPERIMENTAL
Intervention: Prophylactic phenytoin (Dilantin®) for prevention of posttraumatic seizures
Number of subjects: 63
Study: 8392287

Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide, and cisplatin (MIP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vindesine, ifosfamide, and cisplatin (VIP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both MIP and VIP
Number of subjects: 100
Study: 3639894

Group type: EXPERIMENTAL
Intervention: Digital thermometers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercury thermometers
Number of subjects: 0
Study: 30697968

Group type: EXPERIMENTAL
Intervention: Diode laser (1 watt) in addition to scaling and root planing (SRP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo laser treatment in addition to scaling and root planing (SRP)
Number of subjects: 37
Study: 29763976

Group type: EXPERIMENTAL
Intervention: Swaddled bathing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 35
Study: 26986617

Group type: EXPERIMENTAL
Intervention: Open group (aware of the sensor)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Blind group (unaware of the sensor)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups (water filters)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups (cookstoves)
Number of subjects: 170
Study: 25258524

Group type: EXPERIMENTAL
Intervention: Exercise group (n=34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 22803428

Group type: EXPERIMENTAL
Intervention: Compound Danshen Injection (CDI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 120
Study: 20041998

Group type: EXPERIMENTAL
Intervention: Low zinc status
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc supplementation (proposed intervention)
Number of subjects: 0
Study: 18692695

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (alloSCT)
Number of subjects: 0
Study: 16092465

Group type: EXPERIMENTAL
Intervention: Procedure 'I say to myself: I can solve this task'
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Procedure 'I get worried and will have problems solving other tasks too'
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Test performance and academic self-esteem
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Saliva cortisol levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Perceived stress measured with VAS
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Psychological reactions to demands
Number of subjects: 46
Study: 12621778

Group type: EXPERIMENTAL
Intervention: Urine and serum TGF‐beta 1 and IL‐6 levels in patients with type II diabetes mellitus
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Initial TGF‐beta 1 levels exceeding normal values
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Urine TGF‐beta 1 level
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Urine and serum TGF‐beta 1 and IL‐6 levels
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 68
Study: 10342084

Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 177

Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 177
Study: 8961973

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy for 5 years (20 mg/day orally)
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Tamoxifen therapy for 2 years (20 mg/day orally)
Number of subjects: 2937
Study: 1945605

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lederle WCV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Connaught WCV
Number of subjects: 0
Study: 6284687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study: 31092125

Group type: EXPERIMENTAL
Intervention: Multimodal treatment addressing 2 or more factors
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Single factor treatment
Number of subjects: 1000000
Study: 26024828

Group type: EXPERIMENTAL
Intervention: Low dose S‐ILE (1 g/kg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control dose S‐ILE (3 g/kg/d)
Number of subjects: 36
Study: 28514547

Group type: EXPERIMENTAL
Intervention: Etoricoxib therapy
Number of subjects: 296
Study: 24867027

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23031478

Group type: EXPERIMENTAL
Intervention: T1 (2.5 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: T2 (25 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: T3 (250 mg/kg)
Number of subjects: 90
Study: 19544759

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 824

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 824
Study: 17900362

Group type: EXPERIMENTAL
Intervention: Task/context-focused approach
Number of subjects: 220

Group type: COMPARATOR
Intervention: Child-focused remediation approach
Number of subjects: 220
Study: 16060423

Group type: EXPERIMENTAL
Intervention: Auditory modeling plus standard swimming curriculum for the butterfly stroke
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard swimming curriculum for the butterfly stroke
Number of subjects: 37